

# Winnie Yeo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2808532/publications.pdf>

Version: 2024-02-01

274  
papers

18,422  
citations

26630

56  
h-index

13771

129  
g-index

289  
all docs

289  
docs citations

289  
times ranked

17898  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224
2	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	1.6	1,810
3	Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. <i>Journal of Medical Virology</i> , 2000, 62, 299-307.	5.0	604
4	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	1.6	576
5	A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon $\alpha$ -2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1532-1538.	6.3	567
6	Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. <i>Hepatology</i> , 2006, 43, 209-220.	7.3	474
7	Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 536-539.	6.3	449
8	Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 2038-2044.	1.6	443
9	Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. <i>Lancet, The</i> , 1999, 353, 797-801.	13.7	436
10	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
11	Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. <i>British Journal of Cancer</i> , 2004, 90, 1306-1311.	6.4	290
12	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
13	A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 569-577.	0.8	270
14	Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 927-934.	1.6	255
15	New Utility of an Old Marker: Serial $\alpha$ -Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 446-452.	1.6	241
16	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	4.4	217
17	Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. <i>Journal of Medical Virology</i> , 2003, 70, 553-561.	5.0	192
18	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , 2009, 124, 644-652.	5.1	192

#	ARTICLE	IF	CITATIONS
19	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	2.4	191
20	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	3.7	180
21	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
22	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , 2004, 15, 1661-1666.	1.2	153
23	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
24	Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. <i>Clinical Cancer Research</i> , 2002, 8, 1087-92.	7.0	138
25	Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA. <i>Journal of Clinical Oncology</i> , 2004, 22, 3053-3060.	1.6	125
26	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , 2007, 26, 7490-7498.	5.9	106
27	Integration of albuminâ€“bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1300-1306.	2.8	103
28	A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 1998, 34, 2027-2031.	2.8	101
29	Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA101-LBA101.	1.6	100
30	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , 2006, 17, 1083-1089.	1.2	99
31	High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 266-272.	3.9	97
32	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	2.6	96
33	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 5976-5985.	7.0	95
34	Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2004, 88, 209-215.	2.5	88
35	High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. <i>Journal of Viral Hepatitis</i> , 2004, 11, 55-59.	2.0	88
36	Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. , 1999, 59, 263-269.		84

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. <i>Journal of Medical Virology</i> , 2000, 60, 249-255.	5.0	84
38	A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. <i>Annals of Oncology</i> , 2007, 18, 768-774.	1.2	84
39	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
40	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1298-1306.	6.3	83
41	Radiation-recall dermatitis with docetaxel: Establishment of a requisite radiation threshold. <i>European Journal of Cancer</i> , 1997, 33, 698-699.	2.8	82
42	Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1030-1038.	1.1	77
43	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4013-4013.	1.6	76
44	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 340-347.	2.8	75
45	The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study. <i>Psycho-Oncology</i> , 2013, 22, 2831-2839.	2.3	75
46	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 529-535.	2.5	74
47	Targeted therapy of hepatocellular carcinoma: Present and future. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 862-872.	2.8	72
48	Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer. <i>Psycho-Oncology</i> , 2013, 22, 1144-1151.	2.3	72
49	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018, 118, 248-257.	6.4	71
50	Cross-cultural validation of the McGill Quality of Life questionnaire in Hong Kong Chinese. <i>Palliative Medicine</i> , 2001, 15, 387-397.	3.1	70
51	Validation of the Chinese version of the Short-Form Supportive Care Needs Survey Questionnaire (SCNS-34). <i>Psycho-Oncology</i> , 2011, 20, 1292-1300.	2.3	68
52	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	6.4	66
53	The Epigenetic Modifier PRDM5 Functions as a Tumor Suppressor through Modulating WNT/ $\beta$ -Catenin Signaling and Is Frequently Silenced in Multiple Tumors. <i>PLoS ONE</i> , 2011, 6, e27346.	2.5	64
54	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63

#	ARTICLE	IF	CITATIONS
55	Predictors of Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection in Hong Kong. <i>Nursing Research</i> , 2008, 57, 416-425.	1.7	62
56	A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541983650.	2.0	61
57	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , 2007, 45, 1382-1389.	7.3	60
58	Prevalence of Mutations in the BRCA1 Gene Among Chinese Patients With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 882-885.	6.3	59
59	Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 379-384.	1.3	59
60	Knowledge, Perceptions, and Attitudes of Hong Kong Chinese Women on Screening Mammography and Early Breast Cancer Management. <i>Breast Journal</i> , 2005, 11, 52-56.	1.0	58
61	A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 1510-1515.	2.3	58
62	Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. <i>Journal of Medical Virology</i> , 2002, 66, 428-434.	5.0	57
63	Hepatitis B virus reactivation associated with anti-neoplastic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 31-37.	2.8	57
64	Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. <i>Journal of Medical Virology</i> , 2001, 65, 473-477.	5.0	56
65	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	2.6	56
66	Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 466-470.	2.3	54
67	Quality of Life of Palliative Care Patients in the Last Two Weeks of Life. <i>Journal of Pain and Symptom Management</i> , 2002, 24, 388-397.	1.2	54
68	TT virus: a study of molecular epidemiology and transmission of genotypes 1, 2 and 3. <i>Journal of Clinical Virology</i> , 2000, 17, 43-49.	3.1	53
69	Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 63-66.	1.0	53
70	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , 2005, 22, 303-312.	2.5	53
71	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 3984-3992.	4.1	53
72	The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. <i>Journal of Hepatology</i> , 2008, 48, 433-441.	3.7	51

#	ARTICLE	IF	CITATIONS
73	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 307-311.	2.3	50
74	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017, 49, 851-868.	3.0	50
75	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. <i>Radiotherapy and Oncology</i> , 2002, 62, 185-189.	0.6	49
76	Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. <i>Clinical Cancer Research</i> , 2003, 9, 3376-82.	7.0	49
77	Psychosocial impact of breast cancer surgeries in chinese patients and their spouses. <i>Psycho-Oncology</i> , 2004, 13, 132-139.	2.3	48
78	Performance of serum $\alpha$ -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. <i>Hpb</i> , 2014, 16, 366-372.	0.3	48
79	Applicability of albumin–bilirubin–based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1766-1772.	2.8	47
80	Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 221-228.	2.8	47
81	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017, 116, 441-447.	6.4	46
82	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e54522.	2.5	46
83	Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 575.	2.0	45
84	Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs. <i>American Journal of Clinical Dermatology</i> , 2000, 1, 113-116.	6.7	44
85	Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. <i>Radiology</i> , 2014, 270, 607-620.	7.3	44
86	Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. <i>Cancer Letters</i> , 2001, 162, 65-73.	7.2	43
87	Injection sclerotherapy for variceal bleeding in patients with hepatocellular carcinoma: cyanoacrylate versus sodium tetradecyl sulphate. <i>Gastrointestinal Endoscopy</i> , 1998, 47, 235-239.	1.0	42
88	Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. <i>Journal of Viral Hepatitis</i> , 1999, 6, 195-202.	2.0	42
89	Lymphedema and quality of life in Chinese women after treatment for breast cancer. <i>European Journal of Oncology Nursing</i> , 2009, 13, 110-115.	2.1	42
90	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , 2011, 19, 1625-1635.	2.2	42

#	ARTICLE	IF	CITATIONS
91	Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. <i>Cancer Letters</i> , 2001, 167, 183-191.	7.2	41
92	A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2516-2521.	2.3	40
93	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 556-558.	3.7	40
94	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. <i>Journal of Clinical Oncology</i> , 2018, 36, 475-475.	1.6	39
95	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , 2017, 17, 8.	2.6	38
96	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 280-289.	3.9	38
97	Gross Elevation of TT Virus Genome Load in the Peripheral Blood Mononuclear Cells of Cancer Patients. <i>Annals of the New York Academy of Sciences</i> , 2001, 945, 84-92.	3.8	37
98	The evolution of supportive care needs trajectories in women with advanced breast cancer during the 12 months following diagnosis. <i>Supportive Care in Cancer</i> , 2014, 22, 635-644.	2.2	37
99	Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. <i>Journal of Viral Hepatitis</i> , 2000, 7, 448-458.	2.0	36
100	An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 8041-8047.	1.6	36
101	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. <i>Liver International</i> , 2010, 30, 1427-1438.	3.9	35
102	Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 419-427.	2.5	35
103	Brain Metastasis Responding to Gefitinib Alone. <i>Oncology</i> , 2004, 67, 174-178.	1.9	34
104	Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen. <i>Obstetrics and Gynecology</i> , 2013, 121, 943-950.	2.4	33
105	High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumorous tissue of breast cancer. <i>Pathology</i> , 2005, 37, 125-130.	0.6	31
106	Embolization Efficacy and Treatment Effectiveness of Transarterial Therapy for Unresectable Hepatocellular Carcinoma: A Case-Controlled Comparison of Transarterial Ethanol Ablation with Lipiodol-Ethanol Mixture versus Transcatheter Arterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 352-359.	0.5	31
107	Value of quality of life analysis in liver cancer: A clinician's perspective. <i>World Journal of Hepatology</i> , 2017, 9, 867.	2.0	31
108	Role of $\alpha$ -fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , 2009, 5, 889-899.	2.4	30

#	ARTICLE	IF	CITATIONS
109	Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 275-285.	4.9	29
110	Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study. <i>Cancer Management and Research</i> , 2018, Volume 10, 4073-4084.	1.9	29
111	Treating HR+/HER2 <sup>-</sup> breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29
112	Hemorrhagic Pyelitis, Ureteritis, and Cystitis Secondary to Cyclophosphamide: Case Report and Review of the Literature. <i>Gynecologic Oncology</i> , 2000, 76, 223-225.	1.4	28
113	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	4.4	28
114	High Carriage Rate of TT Virus in the Cervices of Pregnant Women. <i>Clinical Infectious Diseases</i> , 2001, 32, 1376-1377.	5.8	27
115	A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II) Tj ETQq1 1 0.784314 1.06 BT /Over	4.1	26
116	The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong. <i>Pharmacoeconomics</i> , 2001, 19, 947-953.	3.3	25
117	Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles. <i>PLoS ONE</i> , 2015, 10, e0140842.	2.5	25
118	Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 2369-2377.	4.1	24
119	Chemotherapy Induced Complete Remission in Malignant Phyllodes Tumor of the Prostate Metastasizing to the Lung. <i>Journal of Urology</i> , 2002, 168, 1104-1105.	0.4	24
120	Goal adjustment influence on psychological well-being following advanced breast cancer diagnosis. <i>Psycho-Oncology</i> , 2016, 25, 58-65.	2.3	24
121	MRI and CT of metastatic hepatocellular carcinoma causing spinal cord compression. <i>Clinical Radiology</i> , 1997, 52, 755-760.	1.1	23
122	Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4012-4012.	1.6	23
123	Transdermal fentanyl for severe cancer-related pain. <i>Palliative Medicine</i> , 1997, 11, 233-239.	3.1	22
124	Nasal lymphoma: Results of local radiotherapy with or without chemotherapy. , 1997, 19, 251-259.		22
125	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 124-130.	2.3	22
126	Effects of Patupilone (Epothilone B; EPO906), a Novel Chemotherapeutic Agent, in Hepatocellular Carcinoma: An in vitro Study. <i>Oncology</i> , 2006, 71, 292-296.	1.9	22



#	ARTICLE	IF	CITATIONS
127	Transarterial Ethanol Ablation of Hepatocellular Carcinoma with Lipiodol-Ethanol Mixture: Phase II Study. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 95-103.	0.5	22
128	Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2011, 38, 721-31.	3.3	22
129	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	4.1	22
130	Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. <i>BMC Women's Health</i> , 2017, 17, 55.	2.0	22
131	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , 2014, 33, 481-91.	4.9	22
132	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 439-450.	7.7	21
133	The association of liver function and quality of life of patients with liver cancer. <i>BMC Gastroenterology</i> , 2019, 19, 66.	2.0	21
134	Quality of life (QOL) for breast cancer patients receiving aprepitant versus placebo for prevention of chemotherapy induced nausea and vomiting. <i>Journal of Clinical Oncology</i> , 2008, 26, 20549-20549.	1.6	21
135	Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. <i>Clinica Chimica Acta</i> , 2001, 313, 179-185.	1.1	20
136	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	1.1	20
137	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1375-1382.	2.6	20
138	Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. , 1998, 82, 2439-2448.		19
139	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 25-33.	6.4	19
140	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). <i>Liver Cancer</i> , 2015, 4, 96-105.	7.7	19
141	Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study. <i>BMC Cancer</i> , 2018, 18, 162.	2.6	19
142	A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. <i>Breast</i> , 2020, 50, 30-38.	2.2	19
143	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-226.	1.6	19
144	Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma-frequency of specific banding patterns at non-diagnostic serum levels. <i>British Journal of Cancer</i> , 1996, 73, 985-988.	6.4	18

#	ARTICLE	IF	CITATIONS
145	A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2000, 89, 543-550.	4.1	18
146	Prognostic Implication of Human Papillomavirus Types and Species in Cervical Cancer Patients Undergoing Primary Treatment. <i>PLoS ONE</i> , 2015, 10, e0122557.	2.5	18
147	Quantitative and genotypic analysis of TT virusinfection in Chinese blood donors. <i>Transfusion</i> , 2001, 41, 1001-1007.	1.6	17
148	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
149	Longitudinal Colour Doppler Study of Superficial Lymph Nodes in Non-Hodgkin's Lymphoma Patients on Chemotherapy. <i>Clinical Radiology</i> , 2000, 55, 110-113.	1.1	15
150	Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2005, 68, 485-492.	1.9	15
151	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 295-300.	2.3	15
152	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. <i>Breast Cancer: Targets and Therapy</i> , 2011, 3, 151.	1.8	15
153	Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 24.	2.4	15
154	Risk factors and natural history of breast cancer in younger Chinese women. <i>World Journal of Clinical Oncology</i> , 2014, 5, 1097.	2.3	15
155	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1529-1535.	2.8	14
156	False-Negative Rate of Abdominal Sonography for Detecting Hepatocellular Carcinoma in Patients with Hepatitis B and Elevated Serum $\alpha$ -Fetoprotein Levels. <i>American Journal of Roentgenology</i> , 2004, 183, 453-458.	2.2	13
157	Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. <i>World Journal of Gastroenterology</i> , 2014, 20, 3135.	3.3	13
158	Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung. <i>Journal of Urology</i> , 2002, 168, 1104-5.	0.4	13
159	Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 247-249.	2.3	12
160	Sonographic findings in masseter-muscle metastases. <i>Journal of Clinical Ultrasound</i> , 2000, 28, 299-302.	0.8	12
161	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1417-1425.	2.3	12
162	Hypermethylation of NF- $\kappa$ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	2.3	12

#	ARTICLE	IF	CITATIONS
163	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. <i>IScience</i> , 2019, 21, 1-18.	4.1	12
164	Rapid healing of an indolent leg ulcer with topical rhGMâ€CSF. <i>Australian and New Zealand Journal of Medicine</i> , 1996, 26, 420-421.	0.5	11
165	Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30 +) T-cell lymphoma. <i>Pathology</i> , 1997, 29, 64-66.	0.6	11
166	Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study. <i>Journal of Hepatology</i> , 2018, 68, S16.	3.7	11
167	Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2002, 13, 655-662.	1.4	10
168	Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. <i>Clinical Oncology</i> , 2007, 19, 333-340.	1.4	10
169	Factors related to sexual health in Chinese women with breast cancer in Hong Kong. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 218-226.	1.1	10
170	State of the Art Antiemetic Therapy for Cancer Patients. <i>Current Oncology Reports</i> , 2016, 18, 2.	4.0	10
171	Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 383-389.	1.9	10
172	Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. <i>Journal of Medical Virology</i> , 2000, 60, 249.	5.0	10
173	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	3.4	9
174	The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 167-180.	2.5	9
175	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	1.6	9
176	Hepatic angiomyelolipoma and tuberous sclerosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 196-198.	2.8	8
177	COSMETIC OUTCOME OF BREASTâ€CONSERVING THERAPY IN CHINESE PATIENTS WITH EARLY BREAST CANCER. <i>ANZ Journal of Surgery</i> , 1997, 67, 771-774.	0.7	8
178	A Comparison of Three Transarterial Lipiodol-Based Formulations for Hepatocellular Carcinoma: In Vivo Biodistribution Study in Humans. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 289-298.	2.0	8
179	A sensitive and specific liquid chromatographyâ€tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2409-2414.	2.3	8
180	Tâ€cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. <i>Journal of Medical Virology</i> , 2011, 83, 1023-1030.	5.0	8

#	ARTICLE	IF	CITATIONS
181	O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING. <i>Journal of Hepatology</i> , 2014, 60, S45-S46.	3.7	8
182	<p>Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mBI in patients with hepatocellular carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2719-2727.	1.9	8
183	Preservation of fertility in premenopausal patients with breast cancer. , 2020, 26, 216-226.		8
184	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. <i>Acta OncolÃ³gica</i> , 2004, 43, 245-251.	1.8	7
185	T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer. <i>Vaccine Journal</i> , 2010, 17, 1315-1321.	3.1	7
186	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	3.6	7
187	Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. <i>Radiotherapy and Oncology</i> , 2000, 54, 201-208.	0.6	6
188	Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. <i>International Journal of Oncology</i> , 2001, 18, 633-8.	3.3	6
189	Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 639-649.	0.5	6
190	Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study. <i>Journal of Hepatology</i> , 2017, 66, S34-S35.	3.7	6
191	Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study. <i>BMC Cancer</i> , 2020, 20, 1013.	2.6	6
192	Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials. <i>Oncologist</i> , 2021, 26, e2288-e2296.	3.7	6
193	A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4103-4103.	1.6	6
194	Unusual Abdominal Tumors. <i>Journal of Clinical Oncology</i> , 2003, 21, 955-956.	1.6	5
195	Longitudinal change of quality of life in the first five years of survival among disease-free Chinese breast cancer survivors. <i>Quality of Life Research</i> , 2021, 30, 1583-1594.	3.1	5
196	Association of high adherence to vegetables and fruits dietary pattern with quality of life among Chinese women with early-stage breast cancer. <i>Quality of Life Research</i> , 2022, 31, 1371-1384.	3.1	5
197	Pre-diagnosis and early post-diagnosis dietary soy isoflavone intake and survival outcomes: A prospective cohort study of early stage breast cancer survivors. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100350.	1.7	5
198	NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2019-002037.	1.6	5

#	ARTICLE	IF	CITATIONS
199	Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. <i>Hong Kong Medical Journal</i> , 2017, 23, 54-62.	0.1	5
200	Higher Level of Sports Activities Participation during Five-Year Survival Is Associated with Better Quality of Life among Chinese Breast Cancer Survivors. <i>Cancers</i> , 2021, 13, 6056.	3.7	5
201	Application of expression genomics in drug development and genomic medicine. <i>Drug Development Research</i> , 2004, 62, 124-133.	2.9	4
202	Reply to Y.X. Koo et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2571-2572.	1.6	4
203	Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 620.	2.6	4
204	Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 2-5.	1.1	4
205	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. <i>Radiology</i> , 2018, 287, 340-348.	7.3	4
206	Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. <i>Quality of Life Research</i> , 2019, 28, 2597-2607.	3.1	4
207	Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine. <i>Data in Brief</i> , 2020, 30, 105421.	1.0	4
208	Dietary Pattern at 18-Month Post-Diagnosis and Outcomes of Breast Cancer Among Chinese Women with Early-Stage Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 4553-4565.	1.9	4
209	Small cell variant of Ki-1 lymphoma associated with myelofibrosis and a novel constitutional chromosomal translocation t(3;4) (q13;q12).. <i>Journal of Clinical Pathology</i> , 1996, 49, 259-262.	2.0	3
210	Hepatocellular carcinoma and lymphoma – two hepatitis B virus-related malignant diseases?. <i>Lancet Oncology</i> , The, 2001, 2, 543.	10.7	3
211	Sequential Chemotherapy with Combination Irinotecan and Cisplatin Followed by Docetaxel for Treatment-Naïve Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 838-844.	1.1	3
212	A Simple and Sensitive High-Performance Liquid Chromatographic Method for Quantification of PXD101, a Histone Deacetylase Inhibitor in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 231-235.	2.0	3
213	Should impaired liver function be held responsible for cognitive impairment and poor health-related quality of life in alcoholic cirrhosis?. <i>Hepatology</i> , 2007, 46, 950-950.	7.3	3
214	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). <i>European Journal of Cancer</i> , 2011, 47, S470-S471.	2.8	3
215	Profile of mood states and quality of life of Chinese postmastectomy women in Hong Kong: Integrating variable- and person-centered approaches. <i>Health Care for Women International</i> , 2016, 37, 906-921.	1.1	3
216	Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. <i>Annals of Oncology</i> , 2017, 28, x57-x58.	1.2	3

#	ARTICLE	IF	CITATIONS
217	Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. <i>Acupuncture in Medicine</i> , 2021, 39, 41-52.	1.0	3
218	The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1163-1175.	2.4	3
219	Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4094-4094.	1.6	3
220	Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2â€“positive breast cancer. <i>Hong Kong Medical Journal</i> , 2018, 24, 56-62.	0.1	3
221	Desmoid tumor mimicking local recurrence of carcinoma of the breast. <i>International Journal of Clinical Oncology</i> , 1998, 3, 49-51.	2.2	2
222	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta OncolÃ³gica</i> , 2005, 44, 177-179.	1.8	2
223	Menopausal symptoms inversely associated with quality of life: findings from a 5-year longitudinal cohort in Chinese breast cancer survivors. <i>Menopause</i> , 2021, 28, 928-934.	2.0	2
224	Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort. <i>BMC Cancer</i> , 2021, 21, 839.	2.6	2
225	Hepatitis B virus reactivation during cytotoxic chemotherapyâ€“enhanced viral replication precedes overt hepatitis. <i>Journal of Medical Virology</i> , 2001, 65, 473-477.	5.0	2
226	Treatment Horizons for Triple-negative Breast Cancer. <i>Hong Kong Journal of Radiology</i> , 0, , 111-118.	0.1	2
227	Reply to L.T. Chen et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e272-e272.	1.6	1
228	Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials. <i>Contemporary Clinical Trials</i> , 2010, 31, 135.	1.8	1
229	Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. <i>Journal of Hepatology</i> , 2017, 66, S620-S621.	3.7	1
230	Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis. <i>Annals of Oncology</i> , 2018, 29, viii81-viii82.	1.2	1
231	Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer. <i>Breast Care</i> , 2020, 15, 655-666.	1.4	1
232	Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. , 2000, 62, 299.		1
233	Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- Prospective validation of the Chinese University Prognostic Index. <i>Journal of Clinical Oncology</i> , 2008, 26, 4591-4591.	1.6	1
234	Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 259-259.	1.6	1

#	ARTICLE	IF	CITATIONS
235	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2011, 29, 205-205.	1.6	1
236	Changes in physical activity from pre-diagnosis to first five years post-diagnosis: A prospective cohort study in Chinese breast cancer patient.. Journal of Clinical Oncology, 2020, 38, e24121-e24121.	1.6	1
237	Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort. Breast Cancer Research and Treatment, 2022, 193, 649-658.	2.5	1
238	Case two. Bleomycin cutaneous toxicity.. Journal of Clinical Oncology, 1998, 16, 1626-1627.	1.6	0
239	Quantitative analysis of circulating tumour cells in breast cancer patients using reverse transcriptase polymerase chain reaction. European Journal of Cancer, 1999, 35, S90.	2.8	0
240	A phase II study of gemcitabine plus oral etoposide (GOE) in treatment of advanced non-small cell lung cancer. European Journal of Cancer, 1999, 35, S255.	2.8	0
241	Reply:. Hepatology, 2007, 46, 1666-1666.	7.3	0
242	0150 The severity of chemotherapy-induced neutropenia in association with PTGS-2 gene polymorphism in breast cancer patients. Breast, 2009, 18, S57.	2.2	0
243	Hepatitis B virus reactivation in association with antineoplastic therapy. Current Hepatitis Reports, 2009, 8, 127-133.	0.3	0
244	421 The expression of CYP1B1 predicts neutropenia after adjuvant chemotherapy in breast cancer patients. European Journal of Cancer, Supplement, 2010, 8, 179.	2.2	0
245	P282 The menopausal status of young Chinese women with early stage breast cancer after adjuvant chemotherapy. Breast, 2011, 20, S68.	2.2	0
246	Histone Deacetylase (HDAC) Inhibition in Hepatocellular Cancer. Annals of Oncology, 2013, 24, i7.	1.2	0
247	RE: Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. Journal of the National Cancer Institute, 2013, 105, 580-580.	6.3	0
248	623: Efficacy of temsirolimus for advanced hepatocellular carcinoma (HCC) - assessment of pS6 as potential prognostic biomarker of response. European Journal of Cancer, 2014, 50, S148.	2.8	0
249	2244 Integration of Albumin-Bilirubin (ALBI) score into current tumour staging system for hepatocellular carcinoma (HCC). European Journal of Cancer, 2015, 51, S414.	2.8	0
250	P088 Early menopause and comorbidities among Chinese breast cancer women after adjuvant chemotherapy. Breast, 2015, 24, S55.	2.2	0
251	Dyslipidaemias after adjuvant chemotherapy in young Chinese breast cancer patients. Annals of Oncology, 2016, 27, vi60.	1.2	0
252	Quality of life of premenopausal Chinese breast cancer patients after adjuvant chemotherapy. Breast, 2017, 32, S28.	2.2	0

#	ARTICLE	IF	CITATIONS
253	Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma. <i>Annals of Oncology</i> , 2017, 28, x116.	1.2	0
254	Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study. <i>Annals of Oncology</i> , 2017, 28, ix87.	1.2	0
255	Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer. <i>Annals of Oncology</i> , 2018, 29, ix2-ix3.	1.2	0
256	Bone health in premenopausal Chinese patients after adjuvant chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2018, 92, S51.	2.8	0
257	Assessment of cancer health literacy among breast cancer patients in Hong Kong. <i>Breast</i> , 2019, 44, S129.	2.2	0
258	Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies. <i>Cancer Biology and Medicine</i> , 2021, 18, 825-832.	3.0	0
259	Immediate toxicity among Chinese patients undergoing adjuvant doxorubicin and cyclophosphamide for early breast cancer- a single institute experience with comparison to historic Western series. <i>European Journal of Cancer</i> , 2002, 38, S132.	2.8	0
260	Quality of life as a predicting factor for survival in 235 patients with inoperable hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2005, 23, 4125-4125.	1.6	0
261	A double-blind placebo-control randomized study of the efficacy of Chinese herbal medicine (CHM) in reduction of cytotoxic chemotherapy-induced toxicity. <i>Journal of Clinical Oncology</i> , 2005, 23, 8157-8157.	1.6	0
262	Correlation of Ki67, topo IIa, MRP1, p53 and p-gp with chemo-responsiveness and survival in patients with hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2006, 24, 4139-4139.	1.6	0
263	Serial alpha-feto protein in predicting radiological response and overall survival of patient with inoperable hepatocellular carcinoma (HCC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 4602-4602.	1.6	0
264	Does severity of underlying chronic liver disease (CLD) affect treatment outcome of hepatocellular carcinoma (HCC) patients undergoing systemic chemotherapy (CT)? <i>Journal of Clinical Oncology</i> , 2009, 27, e15513-e15513.	1.6	0
265	Predictors of treatment outcomes in early stage hepatocellular carcinoma (HCC) detected in a surveillance program. <i>Journal of Clinical Oncology</i> , 2009, 27, 4584-4584.	1.6	0
266	The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4028-4028.	1.6	0
267	Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4058-4058.	1.6	0
268	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
269	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14528-e14528.	1.6	0
270	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 181-181.	1.6	0



#	ARTICLE	IF	CITATIONS
271	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. Journal of Clinical Oncology, 2015, 33, 4073-4073.	1.6	0
272	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15679-e15679.	1.6	0
273	Abstract P1-12-07: Prospective 36-month follow-up to determine changes in body mass index and weight among Chinese breast cancer survivors. , 2019, , .		0
274	Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases. Annals of Oncology, 2019, 30, ix124-ix125.	1.2	0